Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System

Retrospective and Real-Time Monitoring of Heart Failure Across the Yale New Haven Health System Via a Live Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04237701

Acronym

Yale-HF

Enrollment

40000

Registered

2020-01-23

Start date

2019-10-01

Completion date

2030-12-30

Last updated

2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Heart Failure NYHA Class IV, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction

Brief summary

The Yale HF Registry is a live EHR based registry that allows for retrospective and real-time monitoring of Heart Failure case across the Yale New Haven Health System.

Detailed description

Electronic Health Records based registries can be an important resource for precision medicine delivery by understanding the population burden of chronic diseases such as heart failure. These registries can allow for a deeper understanding of gaps in guideline recommended therapies among patients who are under the purview of large, integrated Therefore, we have created a live registry within the integrated Yale New Haven Health System-the Yale Heart Failure Registry-that includes all patients with a diagnosis of HF and has detailed information about demographics, comorbidities, laboratories, imaging, medications, and clinical outcomes (including hospital readmissions). The registry is updated daily and can be queried for clinically relevant questions aimed at quality improvement.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Seen within the Yale New Haven Health System * Diagnosis of heart failure

Exclusion criteria

* Age\<18

Design outcomes

Primary

Measure	Time frame	Description
Number of participants hospitalized for heart failure	10 years	Heart Failure hospitalizations
Doses of therapies that comprise guideline directed medical therapy	10 years	Appropriate use of guideline recommended therapies. This will include doses of beta blockers, ACE inhibitors, ARBs, ARNI, SGLT2i, ICD use.

Countries

United States

Contacts

CONTACTTariq Ahmad, MD MPH

Tariq.ahmad@yale.edu(203) 843-1667

CONTACTNihar Desai, MD MPH

203-767-6399

STUDY_DIRECTORNihar Desai, MD MPH

Yale University

PRINCIPAL_INVESTIGATORTariq Ahmad, MD MPH